The table below shows Amphastar Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$171.17M
$191.84M
$174.41M
$170.53M
$191.21M
$182.39M
Cost of revenue
$100.85M
$93.19M
$87.92M
$85.28M
$89.27M
$87.23M
Gross profit
$70.32M
$98.65M
$86.49M
$85.25M
$101.94M
$95.17M
R&D
$26.74M
$22.35M
$20.08M
$20.10M
$21.08M
$17.65M
AMPH annual revenue (10-K history)
Amphastar Pharmaceuticals, Inc. reported annual revenue of $719.89M for fiscal year 2025. That is down 1.7% from $731.97M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $255.16M (FY 2016) to $719.89M. Figures come from the company's audited annual reports as filed with the SEC.